Renal macrophages play a critical role in kidney diseases, exhibiting both protective and pathogenic functions. They can differentiate into pro-inflammatory M1 macrophages, which exacerbate tissue damage and fibrosis, or anti-inflammatory M2 macrophages, which aid in tissue repair and regeneration. The NLRP3 inflammasome, a complex of proteins including NLRP3, ASC, and pro-caspase-1, is present in renal macrophages and, when activated, leads to the release of pro-inflammatory cytokines (IL-1β and IL-18) and cleavage of Gasdermin D (GSDMD), inducing pyroptosis, a form of inflammatory cell death. This process contributes to renal inflammation, cell death, and dysfunction. The NLRP3–ASC–caspase-1–IL-1β–IL-18 pathway is involved in the pathophysiology of various kidney diseases. Understanding macrophage behavior in kidney inflammation, injury, and fibrosis is crucial for developing therapeutic strategies. Modulating macrophage polarization and targeting NLRP3 inflammasomes could offer new approaches to treat kidney diseases. Renal macrophages originate from different sources, including yolk sac, fetal liver, and bone marrow, and exhibit plasticity in response to disease conditions. M1 macrophages are involved in acute kidney injury and fibrosis, while M2 macrophages promote tissue repair. The interplay between macrophages and inflammasomes, particularly the NLRP3 inflammasome, is essential in kidney disease progression. Targeting these pathways may provide therapeutic benefits in kidney diseases. The role of macrophages in kidney fibrosis is complex, with M2 macrophages playing a key role in tissue repair and fibrosis. The balance between M1 and M2 macrophages is crucial for kidney health. Inflammation and fibrosis are closely linked to macrophage activation and inflammasome signaling. Understanding these mechanisms is essential for developing effective treatments for kidney diseases.Renal macrophages play a critical role in kidney diseases, exhibiting both protective and pathogenic functions. They can differentiate into pro-inflammatory M1 macrophages, which exacerbate tissue damage and fibrosis, or anti-inflammatory M2 macrophages, which aid in tissue repair and regeneration. The NLRP3 inflammasome, a complex of proteins including NLRP3, ASC, and pro-caspase-1, is present in renal macrophages and, when activated, leads to the release of pro-inflammatory cytokines (IL-1β and IL-18) and cleavage of Gasdermin D (GSDMD), inducing pyroptosis, a form of inflammatory cell death. This process contributes to renal inflammation, cell death, and dysfunction. The NLRP3–ASC–caspase-1–IL-1β–IL-18 pathway is involved in the pathophysiology of various kidney diseases. Understanding macrophage behavior in kidney inflammation, injury, and fibrosis is crucial for developing therapeutic strategies. Modulating macrophage polarization and targeting NLRP3 inflammasomes could offer new approaches to treat kidney diseases. Renal macrophages originate from different sources, including yolk sac, fetal liver, and bone marrow, and exhibit plasticity in response to disease conditions. M1 macrophages are involved in acute kidney injury and fibrosis, while M2 macrophages promote tissue repair. The interplay between macrophages and inflammasomes, particularly the NLRP3 inflammasome, is essential in kidney disease progression. Targeting these pathways may provide therapeutic benefits in kidney diseases. The role of macrophages in kidney fibrosis is complex, with M2 macrophages playing a key role in tissue repair and fibrosis. The balance between M1 and M2 macrophages is crucial for kidney health. Inflammation and fibrosis are closely linked to macrophage activation and inflammasome signaling. Understanding these mechanisms is essential for developing effective treatments for kidney diseases.